Meridian to buy diagnostic bio component company:
This article was originally published in Clinica
Meridian Bioscience of Cincinnati, Ohio, has agreed to acquire all outstanding capital stock of OEM Concepts, a developer of biological components used in diagnostic tests. These monoclonal antibodies, which generated over $4m in revenues for Toms-River, New Jersey-based OEM, are form an important component in diagnostic tools for infectious diseases and for monitoring metabolic disorders, pregnancy and cardiac disease. The transaction, which involves a mix of cash and milestone payments, is expected to close within 60-90 days.
You may also be interested in...
FDA action awaits Sun’s manufacturing facility in Halol after it failed to adequately address GMP deviations, though India’s top-ranked drug firm appears to have effectively lowered its dependence on the site that has had a patchy compliance run.
In a surprise to the market, Dr Reddy’s and Hikma have prevailed in challenging six method-of-use patents shielding Amarin’s Vascepa in the US, opening the door for a potential at-risk launch that would likely be challenged by the originator.
Duo will study up to four novel preclinical targets identified by Sitryx that may lead to potential new drugs for autoimmune diseases, which Lilly would then commercialize.